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Objective: To evaluate the potential for
injectable, permanent bone
augmentation by assessing the
biocompatibility and bioactivity of
subperiosteal hydroxylapatite (Radiesse)
deposition in a rat model.

Presently, calcium phosphate cements (CPC),
such as hydroxylapatite (HA), are commonly used for the
alloplastic repair of skull defects. Favorable
characteristics of CPC include customizability, isothermic
setting, biocompatibility, and bioactivity (resorption is
countered by new bone replacement).1 Because of the
chemical properties pertaining to setting, open exposure
is required to use CPC effectively, and thus the
application of CPC is reserved for large defects, such as
those that result from tumor extirpation or extensive
trauma. However, facial plastic surgeons are often faced
with smaller craniofacial deformities that are of aesthetic
concern to the patient but do not warrant the morbidity of
open surgery. Examples would include relatively minor
traumatic bony injury and contour deficiencies from prior
surgery. With these defects in mind, the present study
was designed to examine the biologic characteristics of
injectable HA when interfaced with bone.

Histologic data are summarized in Table 1. While
multinucleated giant cells were often present (Figure 2),
only minimal fibrosis was noted in the specimens. Seven
(2 carrier, 5 HA) out of 13 “subperiosteal” injections were
found to be deep to a disrupted periosteum, while the
remaining 6 were noted to be in the subcutaneous layer
with an intact periosteum beneath. Of note, HA spherules
could not be found at the subcutaneous site for specimen
12 and at both injection sites for specimen 13.

In an attempt to analyze the effect of the injection
plane (subcutaneous vs subperiosteal) and the injectable
(carrier vs HA) on new bone formation, histologic data
was re-organized as depicted in Table 2. Of note,
injections that were intended to be subperiosteal but
were found to be subcutaneous on histologic review were
considered “subcutaneous” (n=6) for the purposes of
statistical analysis. Furthermore, any specimen without
an identifiable injectable (subcutaneous injection site in
specimen 12 and both sites in specimen 13) were
excluded.

Minor deformities of the craniofacial skeleton can be
quite bothersome aesthetically to patients. Radiesse
provides an intriguing option for these patients as its main
biologic constituent, HA, has been used for over 2 decades
in other formulations for open craniofacial reconstruction.2
FDA-approved for the treatment of HIV-related lipoatrophy
and moderate to deep nasolabial folds, Radiesse is wellestablished in facial plastic surgery for soft tissue
augmentation.3,4 Over the years, various studies have
confirmed its safety, longevity and bioactivity (specifically
the stimulation of new collagen deposition) when injected
subcutaneously.5-7 Not surprisingly, off label uses of
Radiesse have arisen as well.8-10

Methods: Fourteen adult Sprague
Dawley rats were injected in the parietal
skull with hydroxylapatite (n=10) or a
carrier gel control (n=4), using a
subperiosteal injection technique on the
right and a subcutaneous injection
technique on the left. At 1, 3, and 6
months, 3 rats (1 negative control, 2
variables) were sacrificed. At 12
months, the remaining 5 rats were
sacrificed. After each harvest, the
calvaria were examined under both light
and polarized microscopy.
Results: The inflammatory response was
limited in all specimens. Injectables
were still present 12 months after the
injection. New bone formation was only
seen when the injection was located
deep to a disrupted periosteum The odd
of new bone formation was 48.949 times
higher (95% CI (2.637, 3759.961), p =
0.002) with subperiosteal hydroxylapatite
injections compared to all other
combinations of injection plane and
injectable.
Conclusion: This preliminary report of
subperiosteal hydroxylapatite (Radiesse)
injection in a rat model has verified the
biocompatibility of injectable
hydroxylapatite at the bony interface and
suggests the potential for new bone
formation.
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METHODS
Fourteen adult Sprague Dawley rats were injected
in the parietal skull with 0.2 ml of HA (n=10) or a carrier
gel control (n=4). In each rat, the left sided injection was
performed just medial to the auricle with a 23-gauge
needle in a subcutaneous plane. On the right side of the
calvarium, a 20-gauge needle was first employed to
elevate the periosteum, and then a 23-gauge needle was
used to inject the material directly on to the underlying
bone (again just medial to the auricle).
Animals were subsequently sacrificed at 4 time
points (1,3,6, and 12 months after the initial injections)
and calvaria were harvested for histologic analysis. Each
of the first 3 harvests included 2 rats from the HA group
and 1 negative control from the carrier gel group. The
12-month harvest again included 1 negative control as
well as the remaining 4 rats from the HA group. All
specimens were stained with hematoxylin and eosin.
Under low power magnification, the injectables were
located and the surrounding tissue was examined.
Proper identification of the injectables was confirmed by
examining and comparing separate samples of the HA
and carrier gel ex vivo (Figure 1). Polarized microscopy
was used to distinguish new (woven) bone from mature
(lamellar) bone.
Odds ratios, p values and 95% confidence
intervals (CI) were calculated using Fisher’s conditional
maximum likelihood estimation. P values < 0.05 were
considered significant.

Reactive bone was not seen in the absence of
periosteal disruption. In 1 of 2 rats with successful
subperiosteal carrier injections, reactive bone was present
at the time of harvest. This rat, specimen 7, was
sacrificed at 6 months (Figure 3). Reactive bone was
observed with subperiosteal HA injections in 4 out of 5
rats- specimen 2 from the 1 month harvest (Figure 4),
specimen 5 from the 3 month harvest, and specimens 12
and 14 from the 12 month harvest. Interestingly, mature
lamellar bone was seen above the HA spherules in
specimen 12, indicating osteointegration. (Figure 5)
A

The odd of new bone formation in the
subperiosteal HA injection group was 48.949 times
higher than the other 3 combinations in aggregate (95%
CI (2.637, 3759.961), p = 0.002). The marginal effect of
subperiosteal injection was also significant, but a discrete
odds ratio could not be computed due to the zero-count
cells in the subcutaneous groups (95% CI (4.068,
infinity), p < 0.001). The marginal effect of HA, however,
was not significant.

B

Figure 1. Amorphous carrier gel (A) and hydroxylapatite
spherules (B) shown under high power magnification

Figure 2. A multinucleated giant
cell is depicted in this high power
magnification view of a 1-mo
hydroxylapatite injection

Figure 3. Under low power,
subperiosteal carrier is noted to
be embedded in new, woven
bone in this 6-mo specimen

To our knowledge, no one to date has examined the
histologic effects of Radiesse injection at the bony interface.
We have now shown that Radiesse is biocompatible and
long-lasting subperiosteally. In designing the study, we did
consider the fact that the trauma of periosteal disruption
could trigger osteoactivity and therefore confound results.
We attempted to control for this with the carrier only
injections; hypothesizing that new bone formation would be
either absent or less pronounced without HA.
Unfortunately, our technique for periosteal disruption was
only successful 54% of the time. Consequently, the
numbers for truly subperiosteal HA and carrier injections
were simply too low to demonstrate a statistically significant
difference in the rate of new bone formation between the
two. Notably, though, the odd of new bone formation in the
subperiosteal HA injection group was significantly higher
than the aggregate of all other combinations of injection
plane and injectable. We were also able to show that the
plane of injection seems to be critical in any effort to induce
osteoactivity as none of the subcutaneous injections
resulted in new bone formation. Lastly, our observations
suggest that, regardless of the mechanism triggering new
bone formation, injectable HA can be osteointegrated.

CONCLUSIONS

Table 1. Summary of binary histologic data. The
presence of periosteal disruption and new bone formation
is indicated with a (+). HA = hydroxylapatite (Radiesse)

Refinements in the technique for subperiosteal
injection are clearly necessary, and further study on a larger
scale is warranted to better elucidate the stimulus for the
osteoactivity we observed histologically.
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Figure 4. Under high power, new
bone formation is seen amidst
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Figure 5. Under high power,
hydroxylapatite spherules from
this 12-mo specimen appear
osteointegrated
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